ClinicalTrials.gg
TerminatedNCT04154787Updated Oct 9, 2024Results posted

Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy

A Phase 2 interventional study of LNP023 and Rituximab in Idiopathic Membranous Nephropathy, sponsored by Novartis Pharmaceuticals. Terminated at 18 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This was a randomized, open-label, two arm, parallel group, proof-of-concept, nonconfirmatory study evaluating the efficacy and safety of LNP023 compared with rituximab in subjects with Idiopathic (primary) membranous nephropathy (iMN) who are at high risk of disease progression defined on the basis of anti- Phospholipase A2 Receptor (PLA2R) antibody titer ≥ 60 RU/mL and proteinuria with urine protein (UP) ≥ 3.5 g/24h.

Read the detailed description

The overall study was planned for a total of 65 weeks and included:

  • A screening phase of up to 12 weeks
  • A treatment phase of up to 24 weeks
  • A post-treatment follow-up period of 29 weeks

As per protocol amendment V01, subjects were randomized 1:1 to LNP023 (investigational drug) or Rituximab (comparator) and followed the below dosing schedule:

  • LNP023 50mg orally b.i.d. for 4 weeks followed by 200mg orally b.i.d. for 20 weeks
  • Rituximab 1g i.v. infusions on Day 1 and Day 15

Initially, per protocol V00, subjects were planned to be randomized in a 1:1:1 ratio to 3 treatment arms:

  • Low dose LNP023: LNP023 10mg orally b.i.d. for 4 weeks followed by 50mg orally b.i.d. for 20 weeks
  • High dose LNP023: 25mg orally b.i.d. for 4 weeks followed by 200mg orally b.i.d. for 20 weeks
  • Rituximab 1g i.v. infusions on Day 1 and Day 15

Following protocol amendment 1 implementation, ongoing subjects were switched to 200mg b.i.d. dose after their initial 4 weeks of treatment.

3 subjects completed treatment under protocol V00. PK/PD data from the 3 completing subjects under protocol V00 are not included in the study results.

The main reason for protocol amendment V01 was to align with the clinical study results obtained from the interim analysis of ongoing phase 2 trials with LNP023 which had shown a dose dependent inhibition of the complement alternative pathway and support best efficacy results with LNP023 at a dose level of 200mg.

The study was early terminated as LNP023 after interim analysis of 12 LNP023 and 14 rituximab subjects because it could already be predicted at that point that the primary goal of superiority of LNP023 vs rituximab in the reduction of UPCR at 24 weeks was not possible to achieve if the study continued to completion.

02

Conditions studied

  • Idiopathic Membranous Nephropathy

Keywords

  • Idiopathic membranous nephropathy
  • MN
03

In context

Glomerulonephritis, Membranous

146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.

This study's enrollment of 37 is below the median of 46 across 105 interventional studies indexed under Glomerulonephritis, Membranous.

Browse Glomerulonephritis, Membranous studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female or male adult (≥18 years) subjects at screening visit with a diagnosis of idiopathic (primary) MN confirmed by renal within 36 months prior to screening. A renal biopsy may be taken at any time during the run-in period to confirm the diagnosis of MN and facilitate subject eligibility, if the most recent biopsy was performed greater than 36 months prior to the screening visit.
  • Anti-PLA2R antibody titer of ≥ 60 RU/mL at screening visit. If sites opt to use a local laboratory, with prior agreement with sponsor, an anti-PLA2R titer performed within 4 weeks prior to screening visit can be used.
  • Urine protein ≥ 3.5 g/24h at screening and baseline visits
  • ≤50% reduction in both anti-PLA2R level and 24h urine protein between screening and baseline
  • Estimated (using the CKD-EPI formula) ≥ 30 mL/min per 1.73 m2 at screening
  • Receiving stable dose at the maximum recommended dose according to local guidelines or maximum tolerated dose of ACEi and/or ARB and/or statins and/or diuretics for at least 8 weeks prior to Day 1
  • Vaccination against Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae (in accordance with local guidelines) at least 28 days prior to Day 1 and no longer than 5 years prior to Day 1.

Exclusion criteria

Exclusion Criteria:

  • Secondary causes of MN, e.g. systemic diseases, solid or haematological , infections or chronic intake of drugs (e.g. gold salts, NSAIDs, penicillamines)
  • Diagnostic renal showing evidence of crescent formation in glomeruli, suggestive of an alternative or additional diagnosis to primary idiopathic MN.
  • Previous treatment with B-cell depleting or B-cell modifying agents such as, but not limited to rituximab, belimumab, daratumomab or bortezomib.
  • Previous treatment with agents such as cyclophosphamide, chlorambucil, mycophenolate mofetil (or equivalent), cyclosporine, tacrolimus or azathioprine within 90 days prior to Day 1. Low dose systemic therapy is permitted, though the subject should have been on stable dose equivalent to ≤10 mg prednisolone for at least 90 days prior to Day 1.
  • Previous treatment with gemfibrozil or strong CYP2C8 inhibitors such as clopidogrel within 7 days prior to Day 1
  • Presence or suspicion (based on judgment of the investigator) of active infection within 30 days prior to Day 1, or history of severe recurrent bacterial infections
  • Known for the use of rituximab, including to the active substance or to murine proteins, or to any of the (sodium citrate, polysorbate 80, sodium chloride, sodium hydroxide, hydrochloric acid, water for injections). Other contra-indications for the use of rituximab, including active, severe infection, patients in a severely immunocompromised state, severe heart failure ( Class IV) or severe, uncontrolled cardiac disease.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    LNP023

    As per protocol V00, participants took LNP023 10 mg orally b.i.d. for 4 weeks followed by LNP023 50 mg orally b.i.d. for 20 weeks. As per protocol amendment V01, participants took LNP023 50mg orally b.i.d. for 4 weeks followed by LNP023 200mg for 20 weeks.

    Drug: LNP023

  • Active comparator
    Rituximab

    Rituximab 1 g i.v. at Day 1 and Day 15

    Drug: Rituximab

Interventions

06

What researchers measure

Primary outcomes

  1. Ratio Between Baseline Urine Protein Creatinine Ratio (UPCR) and Urine Protein Creatinine Ratio at 24 Weeks of Treatment (From 24h Urine Collection)

    The primary endpoint of this study is the ratio between UPCR at 24 weeks of treatment measured in 24h urine and baseline UPCR . To assess the primary objective, the log-transformed ratio to baseline in UPCR was analyzed using a mixed model for repeated measures (MMRM). The results were back transformed and presented on the original scale.

    Time frame: Baseline, Day 113, Day 169

Secondary outcomes

  1. Change From Baseline in Plasma Levels of Circulating Fragment of Factor B (Bb)

    The drug (LNP023) is expected to block the complement alternative pathway dysregulation and thereby should normalize complement biomarker levels in serum. Bb is a biomarker that accurately reflects the level of complement Alternative Pathway activation. Baseline is defined as the last non-missing measurement prior to randomization. Measurements for LNP023 group were done pre-dose.

    Time frame: Baseline, Day 15, Day 29, Day 57, Day 113 and Day 169

  2. Change From Baseline in Plasma Levels of sC5b-9

    Soluble C5b-9 (sC5b-9) is a biomarker of the complement pathway activity that correlate with disease progression. Baseline is defined as the last non-missing measurement prior to randomization. Measurements for LNP023 group were done pre-dose.

    Time frame: Baseline, Day 15, Day 29, Day 57, Day 113, Day 169

  3. Ratio to Baseline of Urine Protein Creatinine Ratio (UPCR) Measured in First Morning Void

    Adjusted geometric mean ratio to baseline of Urine Protein Creatinine Ratio (UPCR) measured in first morning void. First morning void urine sample was collected in the morning of the day before the visit and kept in the fridge.

    Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 266 and Day 378

  4. Number of Participants by Treatment Response at 24 Weeks of Treatment

    Participants were considered complete responders if at 24 weeks of treatment, they showed complete remission of proteinuria (i.e., Urine Protein (UP) ≤ 0.3 g/24h), partial responders if they showed partial remission (i.e., UP \> 0.3g/24h and ≤ 3.5 g/24h and a reduction of UP by \>50% from baseline), and non-responders if UP \>3.5g/24h and/or reduction of UP from baseline \<50%.

    Time frame: Baseline, Day 169

  5. Change From Baseline in (eGFR) Estimated Glomerular Filtration Rate Over Time

    Changes in renal function were assessed via estimated glomerular filtration rate (eGFR). Change in eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

    Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169

  6. Pharmacokinetic Parameter Tmax in Plasma

    Pharmacokinetics of LNP023 : Tmax is the time to reach maximum (peak) plasma drug concentration after dose administration (time). Actual sampling time points were considered for the calculation of PK parameters.

    Time frame: Day 29 and Day 113 (pre-dose and 0.25 hours, 0.5 hours, 1 hour 2 hours, 4 hours and 6 hours post dose)

  7. Pharmacokinetic Parameter Cmax in Plasma

    Pharmacokinetics of LNP023: Cmax is the maximum (peak) observed plasma drug concentration after dose administration (mass x volume-1)

    Time frame: Day 29 and Day 113 (pre-dose and 0.25 hours, 0.5 hours, 1 hour 2 hours, 4 hours and 6 hours post dose)

  8. Pharmacokinetic Parameter AUClast in Plasma

    Pharmacokinetics of LNP023: AUClast is the AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1)

    Time frame: Day 29 and Day 113 (pre-dose and 0.25 hours, 0.5 hours, 1 hour 2 hours, 4 hours and 6 hours post dose)

  9. Pharmacokinetic Parameter AUCtau in Plasma

    Pharmacokinetics of LNP023 : AUCtau is the AUC calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume-1)

    Time frame: Day 29 and Day 113 (pre-dose and 0.25 hours, 0.5 hours, 1 hour 2 hours, 4 hours and 6 hours post dose)

  10. Pharmacokinetics in Urine: Renal Plasma Clearance Derived From 24 Hour Urine Sample

    Pharmacokinetics of LNP023 in urine: Renal plasma clearance derived from 24 hour urine sample

    Time frame: Day 113

07

Results

Posted Jul 5, 2024
Limitations and caveats
Per protocol, participants randomized to the former LNP023 low dose arm (LNP023 10/50 mg b.i.d.) were included in the safety and PK analyses but not in the PD/efficacy analyses as the low number of subjects would not have allowed for a meaningful analysis and interpretation of PD/efficacy data.

Participant flow

Participants took part in 18 investigative sites in 9 countries/regions: Argentina (3), Czech Republic (1), Germany (4), India (2), Netherlands (1), Spain (2), United Kingdom (3), China (1) and Taiwan (1)

Participant flow — Overall Study
MilestoneLNP023 10/50 mg b.i.d.LNP023 200 mg b.i.d.Rituximab
Started31915
Completed3914
Not completed0101
Withdrew: Adverse event010
Withdrew: Patient requires other treatment010
Withdrew: Study terminated by sponsor061
Withdrew: Subject decision010
Withdrew: Suspected lack of efficacy010

Outcome measures

PrimaryRatio Between Baseline Urine Protein Creatinine Ratio (UPCR) and Urine Protein Creatinine Ratio at 24 Weeks of Treatment (From 24h Urine Collection)

The primary endpoint of this study is the ratio between UPCR at 24 weeks of treatment measured in 24h urine and baseline UPCR . To assess the primary objective, the log-transformed ratio to baseline in UPCR was analyzed using a mixed model for repeated measures (MMRM). The results were back transformed and presented on the original scale.

Time frame:
Baseline, Day 113, Day 169
Reported as:
Geometric mean · ratio to baseline
Ratio Between Baseline Urine Protein Creatinine Ratio (UPCR) and Urine Protein Creatinine Ratio at 24 Weeks of Treatment (From 24h Urine Collection)
ratio to baselineLNP023 200 mg b.i.d.Rituximab
Day 1130.94 (0.74 to 1.20)0.89 (0.71 to 1.10)
Day 1690.88 (0.65 to 1.19)0.64 (0.48 to 0.86)
Statistical analysis
  • LNP023 200 mg b.i.d. vs Rituximab · Mixed Models Analysis · p = 0.2670 (Calculated at one-sided 10% level from a lower-tailed test) · Adjusted geometric mean ratio: 1.37 · 95% CI 0.90 to 2.08
SecondaryChange From Baseline in Plasma Levels of Circulating Fragment of Factor B (Bb)

The drug (LNP023) is expected to block the complement alternative pathway dysregulation and thereby should normalize complement biomarker levels in serum. Bb is a biomarker that accurately reflects the level of complement Alternative Pathway activation. Baseline is defined as the last non-missing measurement prior to randomization. Measurements for LNP023 group were done pre-dose.

Time frame:
Baseline, Day 15, Day 29, Day 57, Day 113 and Day 169
Reported as:
Mean · ng/mL
Change From Baseline in Plasma Levels of Circulating Fragment of Factor B (Bb)
ng/mLLNP023 200 mg b.i.d.Rituximab
Day 151520.59 ± 9370.086-417.69 ± 701.667
Day 29-732.00 ± 1412.633-318.46 ± 604.440
Day 57-545.00 ± 1379.201-75.38 ± 787.545
Day 113-877.27 ± 1562.716-219.17 ± 703.568
Day 169-984.00 ± 1794.419-570.00 ± 611.167
SecondaryChange From Baseline in Plasma Levels of sC5b-9

Soluble C5b-9 (sC5b-9) is a biomarker of the complement pathway activity that correlate with disease progression. Baseline is defined as the last non-missing measurement prior to randomization. Measurements for LNP023 group were done pre-dose.

Time frame:
Baseline, Day 15, Day 29, Day 57, Day 113, Day 169
Reported as:
Mean · ng/mL
Change From Baseline in Plasma Levels of sC5b-9
ng/mLLNP023 200 mg b.i.d.Rituximab
Day 15-80.40 ± 98.229-38.49 ± 52.258
Day 29-82.80 ± 118.338-24.51 ± 94.826
Day 57-90.62 ± 108.483-14.02 ± 107.651
Day 113-113.32 ± 108.118-24.95 ± 128.721
Day 169-84.07 ± 96.045-21.76 ± 122.654
SecondaryRatio to Baseline of Urine Protein Creatinine Ratio (UPCR) Measured in First Morning Void

Adjusted geometric mean ratio to baseline of Urine Protein Creatinine Ratio (UPCR) measured in first morning void. First morning void urine sample was collected in the morning of the day before the visit and kept in the fridge.

Time frame:
Baseline, Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 266 and Day 378
Reported as:
Geometric mean · ratio to baseline
Ratio to Baseline of Urine Protein Creatinine Ratio (UPCR) Measured in First Morning Void
ratio to baselineLNP023 200 mg b.i.d.Rituximab
Day 150.94 (0.65 to 1.34)1.15 (0.75 to 1.76)
Day 290.98 (0.70 to 1.36)0.90 (0.60 to 1.35)
Day 571.02 (0.71 to 1.48)0.77 (0.51 to 1.16)
Day 851.03 (0.68 to 1.56)0.75 (0.50 to 1.13)
Day 1131.05 (0.68 to 1.63)0.92 (0.60 to 1.41)
Day 1410.75 (0.48 to 1.19)0.77 (0.48 to 1.23)
Day 1690.72 (0.44 to 1.16)0.55 (0.34 to 0.89)
Day 2660.57 (0.33 to 0.99)0.34 (0.20 to 0.57)
Day 378 (End Of Study)0.37 (0.22 to 0.63)0.46 (0.27 to 0.76)
Statistical analysis
  • LNP023 200 mg b.i.d. vs Rituximab · Mixed Model for Repeated Measures · p = 0.4598 (Calculated from a two-sided test at the 0.05 significance level) · Adjusted geometric mean ratios: 0.81 · 95% CI 0.47 to 1.42Comparison of adjusted geometric mean ratios: Test vs Ref.
  • LNP023 200 mg b.i.d. vs Rituximab · Mixed Model for Repeated Measures · p = 0.4528 (Calculated from a two-sided test at the 0.05 significance level) · Geometric mean ratios: 1.30 · 95% CI 0.65 to 2.61Comparison of adjusted geometric mean ratios: Test vs Ref.
SecondaryNumber of Participants by Treatment Response at 24 Weeks of Treatment

Participants were considered complete responders if at 24 weeks of treatment, they showed complete remission of proteinuria (i.e., Urine Protein (UP) ≤ 0.3 g/24h), partial responders if they showed partial remission (i.e., UP \> 0.3g/24h and ≤ 3.5 g/24h and a reduction of UP by \>50% from baseline), and non-responders if UP \>3.5g/24h and/or reduction of UP from baseline \<50%.

Time frame:
Baseline, Day 169
Reported as:
Count of participants · Participants
Number of Participants by Treatment Response at 24 Weeks of Treatment
ParticipantsLNP023 200 mg b.i.d.Rituximab
Complete00
Partial22
No response77
SecondaryChange From Baseline in (eGFR) Estimated Glomerular Filtration Rate Over Time

Changes in renal function were assessed via estimated glomerular filtration rate (eGFR). Change in eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

Time frame:
Baseline, Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Reported as:
Mean · mL/min/1.73 m^2
Change From Baseline in (eGFR) Estimated Glomerular Filtration Rate Over Time
mL/min/1.73 m^2LNP023 200 mg b.i.d.Rituximab
Day 152.3 ± 12.070.3 ± 8.33
Day 29-0.5 ± 8.536.1 ± 10.44
Day 572.0 ± 11.109.2 ± 21.05
Day 85-1.6 ± 11.5310.2 ± 16.40
Day 1131.2 ± 8.6410.8 ± 15.41
Day 141-1.8 ± 9.107.1 ± 9.29
Day 169-1.3 ± 7.363.1 ± 13.21
SecondaryPharmacokinetic Parameter Tmax in Plasma

Pharmacokinetics of LNP023 : Tmax is the time to reach maximum (peak) plasma drug concentration after dose administration (time). Actual sampling time points were considered for the calculation of PK parameters.

Time frame:
Day 29 and Day 113 (pre-dose and 0.25 hours, 0.5 hours, 1 hour 2 hours, 4 hours and 6 hours post dose)
Reported as:
Median · hours
Pharmacokinetic Parameter Tmax in Plasma
hoursLNP023 10 mg b.i.d.LNP023 25 mg b.i.d.LNP023 50 mg b.i.d. (4-week Administration)LNP023 50 mg b.i.d. (20-week Administration)LNP023 200 mg b.i.d.
Day 292.04 (2.00 to 2.08)2.00 (1.00 to 4.00)2.03 (1.00 to 4.38)——
Day 113———2.05 (2.00 to 2.10)1.00 (0.250 to 6.00)
SecondaryPharmacokinetic Parameter Cmax in Plasma

Pharmacokinetics of LNP023: Cmax is the maximum (peak) observed plasma drug concentration after dose administration (mass x volume-1)

Time frame:
Day 29 and Day 113 (pre-dose and 0.25 hours, 0.5 hours, 1 hour 2 hours, 4 hours and 6 hours post dose)
Reported as:
Mean · ng/mL
Pharmacokinetic Parameter Cmax in Plasma
ng/mLLNP023 10 mg b.i.d.LNP023 25 mg b.i.d.LNP023 50 mg b.i.d. (4-week Administration)LNP023 50 mg b.i.d. (20-week Administration)LNP023 200 mg b.i.d.
Day 291200 ± 7992070 ± 9382140 ± 917——
Day 113———1220 ± 3044810 ± 2850
SecondaryPharmacokinetic Parameter AUClast in Plasma

Pharmacokinetics of LNP023: AUClast is the AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1)

Time frame:
Day 29 and Day 113 (pre-dose and 0.25 hours, 0.5 hours, 1 hour 2 hours, 4 hours and 6 hours post dose)
Reported as:
Mean · hr*ng/mL
Pharmacokinetic Parameter AUClast in Plasma
hr*ng/mLLNP023 10 mg b.i.d.LNP023 25 mg b.i.d.LNP023 50 mg b.i.d. (4-week Administration)LNP023 50 mg b.i.d. (20-week Administration)LNP023 200 mg b.i.d.
Day 295970 ± 41508140 ± 30809920 ± 3960——
Day 113———5940 ± 98922200 ± 15600
SecondaryPharmacokinetic Parameter AUCtau in Plasma

Pharmacokinetics of LNP023 : AUCtau is the AUC calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume-1)

Time frame:
Day 29 and Day 113 (pre-dose and 0.25 hours, 0.5 hours, 1 hour 2 hours, 4 hours and 6 hours post dose)
Reported as:
Mean · hr*ng/mL
Pharmacokinetic Parameter AUCtau in Plasma
hr*ng/mLLNP023 10 mg b.i.d.LNP023 25 mg b.i.d.LNP023 50 mg b.i.d. (4-week Administration)LNP023 50 mg b.i.d. (20-week Administration)LNP023 200 mg b.i.d.
Day 299850 ± 579012800 ± 349016500 ± 5920——
Day 113———10700 ± 164036800 ± 26100
SecondaryPharmacokinetics in Urine: Renal Plasma Clearance Derived From 24 Hour Urine Sample

Pharmacokinetics of LNP023 in urine: Renal plasma clearance derived from 24 hour urine sample

Time frame:
Day 113
Reported as:
Mean · L/hr
Pharmacokinetics in Urine: Renal Plasma Clearance Derived From 24 Hour Urine Sample
L/hrLNP023 50 mg b.i.d. (20-week Administration)LNP023 200 mg b.i.d.
Pharmacokinetics in Urine: Renal Plasma Clearance Derived From 24 Hour Urine Sample0.6021.19 ± 0.668

Adverse events

Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 29 weeks post treatment, up to maximum duration of 53 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LNP023 10/50 mg b.i.d.0/3 (0%)0/3 (0%)2/3 (66.7%)
LNP023 200 mg b.i.d.0/19 (0%)3/19 (15.8%)13/19 (68.4%)
Pooled LNP0230/22 (0%)3/22 (13.6%)15/22 (68.2%)
Rituximab0/15 (0%)4/15 (26.7%)7/15 (46.7%)
Total0/37 (0%)7/37 (18.9%)22/37 (59.5%)
Most frequent serious events
Most frequent serious events
EventLNP023 10/50 mg b.i.d.LNP023 200 mg b.i.d.Pooled LNP023RituximabTotal
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/31/191/222/153/37
Acute kidney injuryRenal and urinary disorders0/30/190/221/151/37
ErythemaSkin and subcutaneous tissue disorders0/30/190/221/151/37
COVID-19 pneumoniaInfections and infestations0/31/191/220/151/37
Lower respiratory tract infectionInfections and infestations0/31/191/220/151/37
Most frequent other events
Showing 10 of 51
Most frequent other events
EventLNP023 10/50 mg b.i.d.LNP023 200 mg b.i.d.Pooled LNP023RituximabTotal
DyspepsiaGastrointestinal disorders1/30/191/221/152/37
Head injuryInjury, poisoning and procedural complications1/30/191/220/151/37
Muscle spasmsMusculoskeletal and connective tissue disorders1/31/192/221/153/37
Epididymal cystReproductive system and breast disorders1/30/191/220/151/37
COVID-19Infections and infestations0/33/193/221/154/37
HeadacheNervous system disorders0/33/193/220/153/37
NasopharyngitisInfections and infestations0/31/191/222/153/37
GoutMetabolism and nutrition disorders0/30/190/222/152/37
FatigueGeneral disorders0/32/192/220/152/37
Oedema peripheralGeneral disorders0/32/192/220/152/37

Baseline characteristics

Age, Continuous
Age, Continuous(years)LNP023 10/50 mg b.i.d.LNP023 200 mg b.i.d.RituximabTotal
Mean55.0 ± 18.5248.9 ± 8.8446.7 ± 15.3348.5 ± 12.43
Sex: Female, Male
Sex: Female, Male(Participants)LNP023 10/50 mg b.i.d.LNP023 200 mg b.i.d.RituximabTotal
Female1416
Male2151431
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LNP023 10/50 mg b.i.d.LNP023 200 mg b.i.d.RituximabTotal
Asian15410
Black Or African American0011
Unknown0011
White214925
08

Study locations

18 sites
  • Novartis Investigative Site
    Caba, Buenos Aires C1181ACH, Argentina
  • Novartis Investigative Site
    Caba, Buenos Aires C1280AEB, Argentina
  • Novartis Investigative Site
    Cordoba, X5016KEH, Argentina
  • Novartis Investigative Site
    Beijing, 100034, China
  • Novartis Investigative Site
    Praha, 12808, Czechia
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Jena, 07740, Germany
  • Novartis Investigative Site
    DehraDun, Uttarakhand 248001, India
  • Novartis Investigative Site
    New Delhi, 110029, India
  • Novartis Investigative Site
    Nijmegen, Netherland 6525 GA, Netherlands
  • Novartis Investigative Site
    Hospitalet de Llobregat, Barcelona 08907, Spain
  • Novartis Investigative Site
    Valencia, Comunidad Valenciana 46017, Spain
  • Novartis Investigative Site
    Taipei, 10002, Taiwan
  • Novartis Investigative Site
    Leicester, LE5 4PW, United Kingdom
  • Novartis Investigative Site
    London, NW3 2QG, United Kingdom
  • Novartis Investigative Site
    Manchester, M13 9WL, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Jan 2023, 37 months.

Results were first posted in Jul 2024, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2019
First posted
Nov 6, 2019
StartActual
Nov 23, 2019
Primary completionActual
Jan 20, 2023
CompletionActual
Jan 20, 2023
Results first posted
Jul 5, 2024
Last update
Oct 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04154787
Responsible party
Sponsor
First posted
Nov 6, 2019
Start date
Nov 23, 2019
Primary completion
Jan 20, 2023
Completion
Jan 20, 2023
Results posted
Jul 5, 2024
Last update
Oct 9, 2024

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iptacopan

Start the discussion